Stockscreener 앱 받기
60.62
0.93%
-0.57
시간 외 거래:
60.62
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - Eagle-Tribune
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference | HALO Stock News - GuruFocus
Halozyme CEO Sets Stage for Major Investor Updates at BofA Healthcare Conference - Stock Titan
Insights into Halozyme Therapeutics's Upcoming Earnings - Nasdaq
Halozyme reports annual meeting results, directors elected - Investing.com Australia
Halozyme reports annual meeting results, directors elected By Investing.com - Investing.com Nigeria
Director Krishnan Mahesh was granted 4,165 shares, increasing direct ownership by 64% to 10,666 units (SEC Form 4) - Quantisnow
Halozyme Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
Halozyme Therapeutics: Still Undervalued Ahead Of Earnings (NASDAQ:HALO) - Seeking Alpha
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Alnylam (ALNY) and Halozyme (HALO) Secure EMA Panel Endorsements - GuruFocus
Halozyme to Report First Quarter 2025 Financial and Operating Re - GuruFocus
Halozyme (HALO) Gains EMA's Endorsement for VYVGART in CIDP Trea - GuruFocus
Director Henderson Jeffrey William sold $271,467 worth of shares (4,497 units at $60.37), decreasing direct ownership by 14% to 28,611 units (SEC Form 4) - Quantisnow
Alnylam, Halozyme among latest firms to win EU backing for drugs (HALO:NASDAQ) - Seeking Alpha
Halozyme Therapeutics Says VYVGART to Treat Rare Autoimmune Disease Receives CHMP Recommendation - marketscreener.com
Halozyme’s CIDP drug nears EU approval after CHMP nod - Investing.com
Halozyme to Report First Quarter 2025 Financial and Operating Results - marketscreener.com
Halozyme Announces argenx Received Positive CHMP Opinion for VYV - GuruFocus
Halozyme Q1 2025 Earnings Call: What to Expect From May 6 Financial Results - Stock Titan
Halozyme Announces Argenx Received Positive CHMP Opinion For Vyvgart (Efgartigimod Alfa) Subcutaneous Injection With Enhanze For CIDP - marketscreener.com
Breakthrough CIDP Treatment Advances: EU Panel Backs First New Therapy Option in Three Decades - Stock Titan
Halozyme shares surge 53% following InvestingPro’s November fair value call By Investing.com - Investing.com UK
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief - MSN
H.C. Wainwright maintains Buy on Halozyme stock, $72 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Halozyme stock, $72 target - Investing.com Australia
Halozyme sues Merck; FDA blames cuts for Vanda delay - BioPharma Dive
Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings) - Benzinga
Halozyme files lawsuit against Merck over SC Keytruda - The Pharma Letter
Halozyme sues Merck over alleged patent infringement By Investing.com - Investing.com South Africa
Halozyme sues Merck, alleging injectable Keytruda will infringe its patents - Endpoints News
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief By Stocktwits - Investing.com India
Merck Faces Lawsuit to Block Launch of Easier-to-Use Keytruda - Bloomberg.com
Halozyme Therapeutics (HALO) Files Lawsuit Against Merck Over Patent Infringement - GuruFocus
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Merck stock flat despite Halozyme patent suit (MRK:NYSE) - Seeking Alpha
Halozyme Files Patent Infringement Lawsuit Against Merck - Nasdaq
Halozyme sues Merck over alleged patent infringement - Investing.com
Halozyme (HALO) Sues Merck Over Keytruda's Subcutaneous Patent Infringement | HALO Stock News - GuruFocus
Halozyme Therapeutics Sues Merck Over Alleged Patent Infringement - marketscreener.com
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation | HALO Stock News - GuruFocus
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation - marketscreener.com
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet - simplywall.st
0.39%
3.66%
자본화:
|
볼륨(24시간):